SELLAS Life Sciences Group, Inc.SLSNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey

SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Profitability This table compares SELLAS Life

globenewswire.com

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –

globenewswire.com

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - - Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -

globenewswire.com

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 –

benzinga.com

What's Going With SELLAS Life Sciences Stock On Wednesday?

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) has surged over 200% over the last six months, with a year-to-date stock jump of around 45%.

defenseworld.net

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw some unusual options trading activity on Monday. Investors purchased 42,324 call options on the stock. This is an increase of approximately 54% compared to the average volume of 27,474 call options. Institutional Investors Weigh In On SELLAS Life Sciences Group Several hedge funds have

defenseworld.net

Solaris Resources (TSE:SLS) Reaches New 52-Week High – Should You Buy?

Solaris Resources Inc. (TSE: SLS - Get Free Report)'s share price reached a new 52-week high during trading on Friday. The stock traded as high as C$13.12 and last traded at C$12.97, with a volume of 146895 shares changing hands. The stock had previously closed at C$12.68. Wall Street Analysts Forecast Growth A number of

globenewswire.com

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advancing innovative treatments for patients with acute myeloid leukemia (AML). Under the agreement, the IMPACT-AML network will conduct a clinical study evaluating SLS009, a highly selective CDK9 inhibitor, enabling access to multiple European clinical sites and patients.

defenseworld.net

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw unusually large options trading on Friday. Traders bought 149,934 call options on the company. This is an increase of approximately 829% compared to the average volume of 16,138 call options. Analyst Upgrades and Downgrades Separately, Weiss Ratings restated a "sell (d-)" rating on shares

defenseworld.net

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report)'s share price gapped up before the market opened on Wednesday. The stock had previously closed at $3.31, but opened at $3.46. SELLAS Life Sciences Group shares last traded at $3.5950, with a volume of 11,566,353 shares trading hands. Wall Street Analysts Forecast Growth Separately,

feeds.benzinga.com

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.

globenewswire.com

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients with AML after second complete remission (CR2).

globenewswire.com

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physicians combat cancer's most resistant forms.

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

globenewswire.com

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that clinical data from its ongoing Phase 2 study of SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine (AZA) and venetoclax (VEN) for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with myelodysplastic syndrome-related changes (AML-MR) after prior VEN-based treatment were presented today at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 – 9, 2025, in Orlando, Florida.

prnewswire.com

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells

defenseworld.net

Stock Traders Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors acquired 15,545 call options on the company. This is an increase of 56% compared to the typical daily volume of 9,947 call options. SELLAS Life Sciences Group Price Performance Shares of NASDAQ SLS opened at

seekingalpha.com

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, President, CEO & Director Dragan Cicic - Senior VP & Chief Development Officer Conference Call Participants Dr. Omer Jamy Dr. Panagiotis Tsirigotis Dr. Philip M. Ryan Sharif Khan, M.D.

globenewswire.com

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in March and August 2024 (the “Existing Warrants”), to purchase up to 22,363,714 shares of its common stock for gross cash proceeds of approximately $31.0 million.

finbold.com

BlackRock just bought this stock with full voting control

The world's largest investment management firm, BlackRock (NYSE: BLK), has disclosed a 5.4% ownership stake in biopharmaceutical company Sellas Life Sciences Group (NASDAQ: SLS).

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance